|
1
|
Liu Z, Delavan B, Roberts R and Tong W:
Lessons learned from two decades of anticancer drugs. Trends
Pharmacol Sci. 38:852–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Owen JL, Kibbi N, Worley B, Kelm RC, Wang
JV, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS, et
al: Sebaceous carcinoma: Evidence-based clinical practice
guidelines. Lancet Oncol. 20:e699–e714. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Migden MR, Rischin D, Schmults CD,
Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim
AM, Chang ALS, et al: PD-1 blockade with cemiplimab in advanced
cutaneous squamous-cell carcinoma. N Engl J Med. 379:341–351. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steren B, Burtness B, Bhatia A, Demirci H,
Shinder R, Yoo D, Tse B and Pointdujour-Lim R: Cemiplimab for
orbital squamous cell carcinoma in 11 cases. Ophthalmic Plast
Reconstr Surg. 38:496–502. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martel A, Lassalle S, Picard-Gauci A,
Gastaud L, Montaudie H, Bertolotto C, Nahon-Esteve S, Poissonnet G,
Hofman P and Baillif S: New targeted therapies and immunotherapies
for locally advanced periocular malignant tumours: Towards a new
‘eye-sparing’ paradigm? Cancers (Basel). 13:28222021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Habib LA, Wolkow N, Freitag SK and Yoon
MK: Advances in immunotherapy and periocular malignancy. Semin
Ophthalmol. 34:327–333. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Na HY, Park JH, Shin SA, Lee S, Lee H,
Chae H, Choung H, Kim N, Chung JH and Kim JE: Targeted sequencing
revealed distinct mutational profiles of ocular and extraocular
sebaceous carcinomas. Cancers (Basel). 13:48102021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zouboulis CC: Sebaceous gland receptors.
Dermatoendocrinol. 1:77–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schneider MR and Paus R: Sebocytes,
multifaceted epithelial cells: Lipid production and holocrine
secretion. Int J Biochem Cell Biol. 42:181–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sherman MH, Downes M and Evans RM: Nuclear
receptors as modulators of the tumor microenvironment. Cancer Prev
Res (Phila). 5:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu K, Zou C and Qin B: The association
between nuclear receptors and ocular diseases. Oncotarget.
8:27603–27615. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shiota M, Fujimoto N, Kashiwagi E and Eto
M: The role of nuclear receptors in prostate cancer. Cells.
8:6022019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Lonard DM and O'Malley BW: The
role of steroid receptor coactivators in hormone dependent cancers
and their potential as therapeutic targets. Horm Cancer. 7:229–235.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Azmahani A, Nakamura Y, McNamara KM and
Sasano H: The role of androgen under normal and pathological
conditions in sebaceous glands: The possibility of target therapy.
Curr Mol Pharmacol. 9:311–319. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kretzschmar K, Cottle DL, Schweiger PJ and
Watt FM: The androgen receptor antagonizes Wnt/β-Catenin signaling
in epidermal stem cells. J Invest Dermatol. 135:2753–2763. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jakobiec FA and Werdich X: Androgen
receptor identification in the diagnosis of eyelid sebaceous
carcinomas. Am J Ophthalmol. 157:687–696.e1-2. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boecker W, Reusch M, Mielke V, Reusch U,
Hallermann C, Loening T, Tiemann M and Buchwalow I: Twenty-Eight
cases of extraocular sebaceous carcinoma: A correlative
clinicopathological and immunohistochemical analysis of extraocular
sebaceous carcinomas and benign sebaceous gland tumors. Am J
Dermatopathol. 43:93–102. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
DeBerardinis RJ and Chandel NS:
Fundamentals of cancer metabolism. Sci Adv. 2:e16002002016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jang M, Kim SS and Lee J: Cancer cell
metabolism: Implications for therapeutic targets. Exp Mol Med.
45:e452013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Danhier P, Bański P, Payen VL, Grasso D,
Ippolito L, Sonveaux P and Porporato PE: Cancer metabolism in space
and time: Beyond the Warburg effect. Biochim Biophys Acta Bioenerg.
1858:556–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thorne JL and Campbell MJ: Nuclear
receptors and the Warburg effect in cancer. Int J Cancer.
137:1519–1527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumagai S, Koyama S, Itahashi K,
Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono
H, et al: Lactic acid promotes PD-1 expression in regulatory T
cells in highly glycolytic tumor microenvironments. Cancer Cell.
40:201–218.e9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dhiman VK, Bolt MJ and White KP: Nuclear
receptors in cancer-uncovering new and evolving roles through
genomic analysis. Nat Rev Genet. 19:160–174. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mulay K, Shah SJ, Aggarwal E, White VA and
Honavar SG: Periocular sebaceous gland carcinoma: Do androgen
receptor (NR3C4) and nuclear survivin (BIRC5) have a prognostic
significance? Acta Ophthalmol. 92:e681–e687. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yunoki T, Miyakoshi A, Otsuka M and
Hayashi A: Clinicopathological features of considerable reduction
in androgen receptor expression in sebaceous gland carcinoma of the
eyelid. Int Ophthalmol. 39:1703–1708. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Na HY, Choe JY, Shin SA, Choung HK, Oh S,
Chung JH, Park M and Kim JE: Proposal of a provisional
classification of sebaceous carcinoma based on hormone receptor
expression and HER2 Status. Am J Surg Pathol. 40:1622–1630. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gerratana L, Basile D, Buono G, De Placido
S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del
Mastro L, et al: Androgen receptor in triple negative breast
cancer: A potential target for the targetless subtype. Cancer Treat
Rev. 68:102–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Traina TA, Miller K, Yardley DA, Eakle J,
Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E,
Kelly C, et al: Enzalutamide for the treatment of androgen
receptor-expressing triple-negative breast cancer. J Clin Oncol.
36:884–890. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang R, Han J, Liang X, Sun S, Jiang Y,
Xia B, Niu M, Li D, Zhang J, Wang S, et al: Androgen receptor
expression and bicalutamide antagonize androgen receptor inhibit
β-catenin transcription complex in estrogen receptor-negative
breast cancer. Cell Physiol Biochem. 43:2212–2225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu M, Yuan Y, Yan P, Jiang J, Ma P, Niu X,
Ma S, Cai H and Yang K: Prognostic significance of androgen
receptor expression in triple negative breast cancer: A systematic
review and meta-analysis. Clin Breast Cancer. 20:e385–e396. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sutton LM, Cao D, Sarode V, Molberg KH,
Torgbe K, Haley B and Peng Y: Decreased androgen receptor
expression is associated with distant metastases in patients with
androgen receptor-expressing triple-negative breast carcinoma. Am J
Clin Pathol. 138:511–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Latorre V, Sevilla LM, Sanchis A and Perez
P: Selective ablation of glucocorticoid receptor in mouse
keratinocytes increases susceptibility to skin tumorigenesis. J
Invest Dermatol. 133:2771–2779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Conzen SD: Recent advances in
understanding glucocorticoid receptor function in cancer. Clin Adv
Hematol Oncol. 15:338–340. 2017.PubMed/NCBI
|
|
35
|
Abduljabbar R, Negm OH, Lai CF, Jerjees
DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green
AR, et al: Clinical and biological significance of glucocorticoid
receptor (GR) expression in breast cancer. Breast Cancer Res Treat.
150:335–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Skor MN, Wonder EL, Kocherginsky M, Goyal
A, Hall BA, Cai Y and Conzen SD: Glucocorticoid receptor antagonism
as a novel therapy for triple-negative breast cancer. Clin Cancer
Res. 19:6163–6172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Noureddine LM, Trédan O, Hussein N, Badran
B, Le Romancer M and Poulard C: Glucocorticoid Receptor: A
multifaceted actor in breast cancer. Int J Mol Sci. 22:44462021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Puhr M, Hoefer J, Eigentler A, Ploner C,
Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, et al:
The glucocorticoid receptor is a key player for prostate cancer
cell survival and a target for improved antiandrogen therapy. Clin
Cancer Res. 24:927–938. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McNamara KM, Kannai A and Sasano H:
Possible roles for glucocorticoid signalling in breast cancer. Mol
Cell Endocrinol. 466:38–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Block TS, Murphy TI, Munster PN, Nguyen DP
and Lynch FJ: Glucocorticoid receptor expression in 20 solid tumor
types using immunohistochemistry assay. Cancer Manag Res. 9:65–72.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kost BP, Beyer S, Schröder L, Zhou J, Mayr
D, Kuhn C, Schulze S, Hofmann S, Mahner S, Jeschke U and Heidegger
H: Glucocorticoid receptor in cervical cancer: An
immunhistochemical analysis. Arch Gynecol Obstet. 299:203–209.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gandhi S, Elkhanany A, Oshi M, Dai T,
Opyrchal M, Mohammadpour H, Repasky EA and Takabe K: Contribution
of immune cells to glucocorticoid receptor expression in breast
cancer. Int J Mol Sci. 21:46352020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kanai A, McNamara KM, Iwabuchi E, Miki Y,
Onodera Y, Guestini F, Khalid F, Sagara Y, Ohi Y, Rai Y, et al:
Significance of glucocorticoid signaling in triple-negative breast
cancer patients: A newly revealed interaction with androgen
signaling. Breast Cancer Res Treat. 180:97–110. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mitani Y, Lin SH, Pytynia KB, Ferrarotto R
and El-Naggar AK: Reciprocal and autonomous glucocorticoid and
androgen receptor activation in salivary duct carcinoma. Clin
Cancer Res. 26:1175–1184. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Petersen C, Nielsen MD, Andersen ES, Basse
AL, Isidor MS, Markussen LK, Viuff BM, Lambert IH, Hansen JB and
Pedersen SF: MCT1 and MCT4 expression and lactate flux activity
increase during white and brown adipogenesis and impact adipocyte
metabolism. Sci Rep. 7:131012017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fiaschi T, Marini A, Giannoni E, Taddei
ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P and
Chiarugi P: Reciprocal metabolic reprogramming through lactate
shuttle coordinately influences tumor-stroma interplay. Cancer Res.
72:5130–5140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Payen VL, Mina E, Van Hée VF, Porporato PE
and Sonveaux P: Monocarboxylate transporters in cancer. Mol Metab.
33:48–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
de la Cruz-Lopez KG, Castro-Munoz LJ,
Reyes-Hernandez DO, Garcia-Carranca A and Manzo-Merino J: Lactate
in the regulation of tumor microenvironment and therapeutic
approaches. Front Oncol. 9:11432019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ufuk A, Garner T, Stevens A and Latif A:
Monocarboxylate transporters are involved in extracellular matrix
remodelling in pancreatic ductal adenocarcinoma. Cancers (Basel).
14:12982022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kobayashi M, Narumi K, Furugen A and Iseki
K: Transport function, regulation, and biology of human
monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4). Pharmacol
Ther. 226:1078622021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Choi JW, Lee Y, Kim H, Cho HY, Min SK and
Kim YS: Coexpression of MCT1 and MCT4 in ALK-positive anaplastic
large cell lymphoma: Diagnostic and therapeutic implications. Am J
Surg Pathol. 46:241–248. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yuan C, Zhang J, Lou J and Wang S, Jiang
Y, Wu F and Wang S: Comprehensive Analysis of Monocarboxylate
Transporter 4 (MCT4) expression in breast cancer prognosis and
immune infiltration via integrated bioinformatics analysis.
Bioengineered. 12:3850–3863. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tong YH, Hu XP, Xiang XP and Fang L: High
expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1,
predicts poor prognosis in patients with non-small cell lung
cancer. Transl Cancer Res. 10:1336–1345. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
de Carvalho PA, Bonatelli M, Cordeiro MD,
Coelho RF, Reis S, Srougi M, Nahas WC, Pinheiro C and Leite KRM:
MCT1 expression is independently related to shorter cancer-specific
survival in clear cell renal cell carcinoma. Carcinogenesis.
42:1420–1427. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang Y, Qin L, Chen W, Chen Q, Sun J and
Wang G: Novel strategies to improve tumour therapy by targeting the
proteins MCT1, MCT4 and LAT1. Eur J Med Chem. 226:1138062021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Takenaga K, Koshikawa N, Akimoto M,
Tatsumi Y, Lin J, Itami M and Nagase H: MCT4 is induced by
metastasis-enhancing pathogenic mitochondrial NADH dehydrogenase
gene mutations and can be a therapeutic target. Sci Rep.
11:133022021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Miranda-Gonçalves V, Gonçalves CS, Granja
S, Vieira de Castro J, Reis RM, Costa BM and Baltazar F: MCT1 Is a
new prognostic biomarker and its therapeutic inhibition boosts
response to temozolomide in human glioblastoma. Cancers (Basel).
13:34682021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chandel V, Maru S, Kumar A, Kumar A,
Sharma A, Rathi B and Kumar D: Role of monocarboxylate transporters
in head and neck squamous cell carcinoma. Life Sci. 279:1197092021.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Barron CR and Smoller BR: GLUT1 expression
in cutaneous sebaceous lesions determined by immunohistochemical
staining patterns. Dermatopathology (Basel). 8:258–264. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Halford S, Veal GJ, Wedge SR, Payne GS,
Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM,
et al: A Phase I dose-escalation study of AZD3965, an oral
monocarboxylate transporter 1 inhibitor, in patients with advanced
cancer. Clin Cancer Res. 29:1429–1439. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Swaika A, Hammond WA and Joseph RW:
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Mol Immunol. 67((2 Pt A)): 4–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Saliba M, Shaheen M, Hajj RE, Abbas F,
Bashir S, Sheikh UN, Mahfouz R, Loya A and Khalifeh I: PD-L1
expression in sebaceous carcinomas. Cancer Immunol Immunother.
70:1907–1915. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wolkow N, Jakobiec FA, Afrogheh AH, Pai SI
and Faquin WC: High expression of programmed death ligand 1 and
programmed death ligand 2 in ophthalmic sebaceous carcinoma: The
case for a clinical trial of checkpoint inhibitors. Am J
Ophthalmol. 220:128–139. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jayaraj P and Sen S: Evaluation of PD-L1
and PD-1 expression in aggressive eyelid sebaceous gland carcinoma
and its clinical significance. Indian J Ophthalmol. 67:1983–1987.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J,
Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B and Tetzlaff MT: High
expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.
Oncoimmunology. 7:e14758742018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Smith J, Robida MD, Acosta K, Vennapusa B,
Mistry A, Martin G, Yates A and Hnatyszyn HJ: Quantitative and
qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Diagn Pathol. 11:442016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
